Uveal melanoma is a rare cancer that starts inside the eye. It is the most common primary cancer of the eye in adults, but it is still uncommon in the broader population. Care depends on a coordinated team that usually includes an ocular oncologist, a retina specialist, and a medical oncologist for systemic risk. Monitoring after treatment is a long process, because the cancer can spread, especially to the liver, years after the eye itself has been treated. A new blood test that looks for circulating tumor DNA, launched in the United States in 2026, is meant to add another signal to that monitoring, not to replace imaging or specialist follow-up.
At a Glance
- Uveal melanoma is a rare cancer that starts in the pigmented layer of the eye.
- Monitoring usually combines eye exams, imaging, and liver-focused surveillance over many years.
- A blood test that looks for circulating tumor DNA is designed to complement imaging, not replace it.
- The test belongs in a specialist ocular oncology care plan, not in self-ordered testing.
- New vision changes, eye pain, flashes, floaters, or new symptoms your care team flagged should be reported promptly.
What Uveal Melanoma Is
The uvea is the middle pigmented layer of the eye that includes the iris, the ciliary body, and the choroid. Uveal melanoma develops when pigmented cells in this layer grow into a tumor. Most uveal melanomas affect the choroid, the layer behind the retina.
Common ways uveal melanoma is found include:
- A routine dilated eye exam where the eye doctor notices a suspicious pigmented lesion
- New symptoms such as floaters, flashes, blurred vision, or a visual field defect
- Findings on imaging done for another eye reason
When uveal melanoma is suspected, the patient is usually referred to an ocular oncologist for confirmation, staging, and treatment planning. Treatment may include radiation therapy, surgery, or, in selected cases, removal of the eye. The choice depends on tumor size, location, vision in the eye, and patient factors.
Why Monitoring Continues for Years
Even after successful treatment of the eye, uveal melanoma can spread to other parts of the body, most commonly the liver. The risk of spread is shaped by tumor size, location, and genetic features identified at diagnosis. For some patients, the risk is low. For others, it is meaningful and warrants long-term surveillance.
Standard surveillance often includes:
- Regular ocular oncology follow-up
- Liver imaging, such as MRI or ultrasound, at intervals set by the team
- Blood work to assess liver function
- Other testing based on individual risk and the team's protocol
Monitoring continues for years because spread can occur late. The point is to detect any sign of disease activity early, when more treatment options remain available.
What Circulating Tumor DNA Testing Adds
Circulating tumor DNA, or ctDNA, refers to tiny fragments of tumor genetic material that can sometimes appear in the bloodstream. A blood test designed to detect ctDNA can look for those fragments in patients who are being monitored for cancer.
For uveal melanoma, a blood-based ctDNA test does not replace imaging or specialist exams. It adds a different type of information. Imaging shows anatomy. Liver function tests show how the liver is working. ctDNA testing can sometimes give a molecular signal of disease activity earlier than imaging shows it, in selected settings.
The 2026 launch of a ctDNA test for uveal melanoma monitoring in the United States is part of a broader effort to combine these signals into a fuller picture of how the disease is behaving in an individual patient.
Why a Specialist Care Team Still Drives the Plan
A blood test result without context is hard to interpret. A ctDNA result that suggests disease activity changes the conversation only if it leads to a clear next step, such as additional imaging, a change in monitoring frequency, or referral to a medical oncologist. A negative result is reassuring but does not mean monitoring can stop.
That is why these tests belong in the hands of a specialist team that already knows the patient, the original tumor characteristics, and the surveillance plan. Self-ordered tests outside that framework can create anxiety or false reassurance without leading to better care.
What Patients Should Track Day to Day
Beyond formal surveillance, patients are encouraged to:
- Keep all scheduled eye and oncology visits, even when feeling well
- Report new vision changes promptly
- Note any new general symptoms the care team asked them to watch, such as unexplained weight loss or new abdominal symptoms
- Maintain healthy habits that support cancer monitoring, including avoiding tobacco and managing other health conditions
- Ask questions when test results or recommendations are unclear
The strongest patient role in cancer surveillance is consistency. Showing up to monitoring appointments is the most important part of catching problems early.
When to Seek Care
Patients with a history of uveal melanoma should contact their care team for:
- New vision changes in either eye
- New flashes or many new floaters
- Eye pain
- Loss of part of the visual field
- Unexplained weight loss
- New abdominal pain or jaundice (yellowing of skin or eyes)
- Any symptom your oncology team specifically told you to report
These are not always related to disease activity, but they deserve a real evaluation rather than waiting for the next routine visit.
Questions to Ask Your Oncology Team
- Would ctDNA testing add useful information in my case?
- How often would testing happen, and how does it fit with imaging?
- What result would change my follow-up plan?
- Who will explain results to me and at what timing?
- What symptoms should make me call between visits?
- What is my long-term surveillance schedule?
Frequently Asked Questions
Does a positive ctDNA result mean the cancer has come back?
Not by itself. A positive result is a signal that needs to be interpreted in the context of imaging, exam findings, and the patient's history. The care team uses the result as one input alongside other tests before deciding next steps.
Is uveal melanoma the same as skin melanoma?
No. Uveal melanoma starts in the pigmented cells of the eye and behaves differently from skin melanoma. It has its own treatment pathways, surveillance plans, and patterns of spread, and the medical and ocular oncology teams that manage it are usually specialized.
Can I ask my primary care doctor for a ctDNA test for uveal melanoma?
Specialized molecular tests for uveal melanoma are usually ordered through ocular oncology or medical oncology teams that manage the disease. A primary care visit can be part of the broader care plan, but specialized testing belongs in the hands of clinicians who follow this cancer regularly.
Will monitoring ever stop?
Monitoring schedules taper over time but often continue for many years, because spread can occur late. The exact schedule depends on tumor characteristics, genetic features at diagnosis, and patient risk. The ocular oncology team will explain what your long-term plan looks like.
